Cyclacel Limited

Erasmus University Medical Center

Erasmus University Medical Centre

Ribotargets Limited

Gendel Limited

Minos Biosystems Limited

M. L. Laboratories Plc

Cobra Therapeutics Limited

Erasmus University Medical Center Rotterdam

Craig, Roger Kingdon

Roger Kingdon Craig

Franklin Gerardus Grosveld

Richard Wilhelm Janssens

Dubravka Drabek

John Colyer

Alistair Simpson Irvine

Ernie De Boer

Marinus Johannes Van Haperen

Richard Willhelm Janssens

Jonathan Karn

Charalambos Savakis

Anthony Patrick McHale

Tao Chen

Rodney Warren Zemmel

Peter Jonathan Gasking Butler

Simon Richard Green

Frank Grosveld

David R Thatcher

Adrian Haines

Ross Owen Phillips

Franklin Geradus Grosveld

John Hamilton Welsh

Ana Maria Rollan Haro

Mokdad Mezna

Antonio Maschio

Ana Maria Rollan-Haro

Magnus Johannes Van Haperen

Richard W Erasmus Univ MedCtr R'Dam Janssens

Dubravka Erasmus Univ Med Ctr R'Dam Drabek

Franklin G Erasmus Univ MedCtrR'Dam Grosveld

A transgenic non-human mammal containing a heterologous lambda light chain gene locus, and/or a heterologous kappa light chain gene locus, and/or a heterologous heavy chain gene locus, each of which can re-arrange so that immunoglobulin heavy and light chain genes are formed and expressed in B-cells following antigen challenge.

Antibody production

The present invention relates to a method of generation of fully functional heavy chain-only antibodies in transgenic mice in response to antigen challenge.

Methods of making heavy chain only antibodies using transgenic animals

The present invention relates to a method for the generation of Vheavy chain-only antibodies in a transgenic non-human mammal. In particular, the present invention relates to a method for the production of a Vheavy chain-only antibody in a transgenic non-human mammal comprising the step of expressing more than one heterologous Vheavy chain locus in that mammal.

Generation of heavy-chain only antibodies in transgenic animals

The present invention provides a high affinity, antigen-specific, soluble heavy chain-only antibody which: lacks hallmark camelid-related amino acid substitutions and has FR2 substitutions which are not found in antibodies which comprise heavy and light chain; shows increased net hydrophobicity within CDR1 and an increased number of charged amino acids present in CDR3; and comprises one or more amino acid substitutions within the framework &#x3b2;-pleated sheet leading to increased net hydrophobicity within FR1 and increased number of charged amino acids present in FR3. Also provided are VH domains having the same properties, gene segments for their production, methods for their production, transgenic animals and uses of the antibody of the VH domains in therapy.

Soluble heavy-chain only antibodies

The present invention relates to the manufacture of a diverse repertoire of functional heavy chain-only antibodies that undergo affinity maturation, and uses thereof. The invention also relates to the manufacture and use of a diverse repertoire of class-specific heavy chain-only antibodies and to the manufacture and use of multivalent polypeptide complexes with antibody heavy chain functionality, preferably antibody heavy chain binding functionality, constant region effector activity and, optionally, additional effector functions. The present invention also relates to a method of generation of fully functional heavy chain-only antibodies in transgenic mice in response to antigen challenge. In particular, the present invention relates to a method for the generation of human antigen-specific, high affinity, heavy chain-only antibodies of any class, or mixture of classes and the isolation and expression of fully functional VH antigen-binding domains.

Binding molecules

Soluble 'heavy-chain only' antibodies

A method of inducing transposition in a transgenic embryo, sperm and egg is described, comprising the steps of (a) generating a first adult transgenic organism comprising within its genome one or more copies of a transposon; (b) generating a second adult transgenic organism comprising within its genome one or more copies of a gene encoding a transposase cognate for the transposon and/or a sequence capable of regulating expression of the gene encoding the transposase; (c) crossing the first adult transgenic organism with the second transgenic adult organism to provide a progeny which comprises, in the genome of one or more of its cells, both (i) one or more copies of the transposon and (ii) a gene encoding a transposase cognate for the transposon, wherein the gene encoding the transposase is under the control of one or more inducible regulatory sequences which permit expression of the transposase, and (d) expressing the gene encoding the transposase in the embryo, sperm or egg to cause mobilization of the transposon within a portion of the tissues or cells of the progeny. Using the method, mobilization of a transposon can advantageously be induced at predetermined stages of development of an embryo, sperm or egg and the mutated gene of a single cell may be replicated in subsequent cell divisions, resulting in groups of cells which are essentially homogenous for the transposed gene.

Transgenic mice generated by transposition and uses thereof

Described and claimed is the combined use of an electric field and ultrasound to ablate a cell or tissue, the use of ultrasound to disrupt a nucleated cell which has previously been electrosensitised by exposure to an electric field, and the use of an electric field for sensitising a nucleated cell to ultrasound. We furthermore disclose the use of electricity to disrupt a nucleated cell which has previously been sensitised by exposure to ultrasound, and the use of ultrasound for sensitising a nucleated cell to electricity.

Ultrasound therapy

This invention relates to a method for analyzing a sample comprising: immobilising a polypeptide to a physical support; contacting the immobilised polypeptide with a test sample which may contain an agent capable of modifying the immobilised polypeptide; contacting the immobilised polypeptide with a binding partner polypeptide, wherein the binding of this partner polypeptide to the immobilised polypeptide is at least partly dependent on the modification state of the immobilised polypeptide; and measuring the association of the binding partner polypeptide to the immobilised polypeptide.

Compositions and methods for monitoring the modification state of a pair of polypeptides

The invention relates to a method for producing a protein of interest comprising transforming a target insect with a non-viral expression system that expresses the protein in the insect larvae, breeding the insect to produce larvae, culturing the larvae and isolating the protein from the larvae.

Protein production system

Growing community of inventors

Cheshire, United Kingdom

Roger Kingdon Craig